Altimmune Inc (NASDAQ: ALT) is one of the top five AI stocks to consider for 2023, as the global AI boom is predicted to reach over $1.81 trillion by 2030, according to Grand View Research. Altimmune, a healthcare sector company, has experienced a decline in annual sales by 30.84% over the past five years. However, its average yearly earnings per share have been noted at a positive 15.26%.
Altimmune has a float of $53.19 million and has outstanding shares totaling $53.73 million. Despite the slip in sales, the company has shown resilience with 52 employees.
When evaluating the stock, it’s important to consider investor sentiment. Altimmune has an insider ownership of 1.01% and institutional ownership of 65.84%. Recent insider transactions include a director purchasing 300 shares at a rate of $2.88, bringing their total ownership to 29,785 shares. Additionally, the company’s CFO bought 10,000 shares for $4.31, resulting in a transaction worth $43,140 and bringing their total ownership to 22,010 shares.
For the last quarter, Altimmune posted earnings per share (EPS) of -$0.39, surpassing the estimated -$0.42 by $0.03. The company also achieved a return on equity of -44.07%. Wall Street analysts predict a further improvement, forecasting earnings of -0.46 per share for the current fiscal year and 15.26% per share for the next fiscal year.
Altimmune’s performance indicators reveal a quick ratio of 12.89 for the past quarter and a price to sales ratio of 468.22 for the trailing twelve months. The company’s diluted EPS for the trailing twelve months stands at -1.54, with predictions of -0.42 for the next quarter and -1.82 in one year’s time.
Altimmune saw its 5-day average volume at 1.41 million, a decrease from its year-to-date volume of 1.62 million. The stock’s Stochastic %D was 26.13% in the previous 9 days, indicating a slightly bearish trend. Additionally, Altimmune showed a historical volatility of 59.52% in the past 14 days, lower than the 62.39% volatility in the past 100 days.
Currently, Altimmune’s 50-day Moving Average is $2.55, while its 200-day Moving Average is $5.04. The stock faces resistance levels at $2.52, $2.60, and $2.71, with $2.34 and $2.23 as support levels.
With 53,729K shares outstanding and a market cap of $131.10 million, Altimmune’s sales have totaled -70K annually with an income of -84,710K. Last quarter, the company’s sales reached 10K, while income amounted to -16,060K.
Considering Altimmune’s potential in the AI industry and its financial performance, it could be a stock worth considering for investors looking to capitalize on the AI revolution.
